BCYC Bicycle Therapeutics plc: Enterprise Value-to-Revenue Multiple

bicycletherapeutics.com (BCYC) - corporate logo

Bicycle Therapeutics (BCYC) creates innovative oncology platforms through strategic alliances with pharmaceutical industry leaders. The EV-to-revenue multiple demonstrates market value dynamics, while -3607.98 determines the latest valuation metric. Primary risks are associated with potential drug toxicity during clinical stages. High business scalability ensures low production costs relative to the significant selling price of the medications.

Bicycle Therapeutics - BCYC Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Bicycle Pharma - analytical breakdowns and key metrics (BCYC)

- company stock capitalization data:
Fundamental company valuation:BCYC (Bicycle Therapeutics)
Original product of Bicycle Therapeutics PLC

To select high-quality assets, an investor must compare a business's market value with its actual ability to generate cash flow. The EV/Sales metric measures the total enterprise value, including debt minus cash, relative to annual sales volume. For Bicycle Therapeutics (BCYC), whose revenues depend on partner payments, this indicator reflects market expectations for future therapeutic successes. By analyzing the historical EV/Sales trend, one can determine the degree of company overvaluation relative to current development stages.